Ovarian Cancer

State of the Art and Future Directions in Translational Research

  • George Coukos
  • Andrew Berchuck
  • Robert Ozols
Conference proceedings

DOI: 10.1007/978-0-387-68969-2

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 622)

Table of contents (23 papers)

  1. Front Matter
    Pages i-xi
  2. Ovarian Cancer Detection and Pathogenesis

    1. Potential and Limitations in Early Diagnosis of Ovarian Cancer
      Nicole Urban, Charles Drescher
      Pages 3-14
    2. Classification of Ovarian Cancer: A Genomic Analysis
      Michael P. Stany, Tomas Bonome, Fred Wamunyokoli, Kristen Zorn, Laurent Ozbun, Dong-Choon Park et al.
      Pages 23-33
    3. Epigenetic Markers of Ovarian Cancer
      Caroline A. Barton, Susan J. Clark, Neville F. Hacker, Philippa M. O’Brien
      Pages 35-51
    4. Role of Genetic Polymorphisms in Ovarian Cancer Susceptibility: Development of an International Ovarian Cancer Association Consortium
      Andrew Berchuck, Joellen M. Schildkraut, C. Leigh Pearce, Georgia Chenevix-Trench, Paul D. Pharoah
      Pages 53-67
    5. MicroRNA in Human Cancer: One Step Forward in Diagnosis and Treatment
      Lin Zhang, Nuo Yang, George Coukos
      Pages 69-78
    6. Ovarian Carcinogenesis: An Alternative Hypothesis
      Jurgen M. J. Piek, Paul J. van Diest, René H. M. Verheijen
      Pages 79-87
    7. BRCA1-Induced Ovarian Oncogenesis
      Louis Dubeau
      Pages 89-97
    8. Role of p53 and Rb in Ovarian Cancer
      David C. Corney, Andrea Flesken-Nikitin, Jinhyang Choi, Alexander Yu. Nikitin
      Pages 99-117
    9. Ovulatory Factor in Ovarian Carcinogenesis
      William J. Murdoch
      Pages 119-128
  3. Ovarian Cancer Therapeutics

    1. Ovarian Cancer: Can We Reverse Drug Resistance?
      David S. P. Tan, Joo Ern Ang, Stan B. Kaye
      Pages 153-167
    2. Syngeneic Mouse Model of Epithelial Ovarian Cancer: Effects of Nanoparticulate Paclitaxel, Nanotax®
      Katherine F. Roby, Fenghui Niu, Roger A. Rajewski, Charles Decedue, Bala Subramaniam, Paul F. Terranova
      Pages 169-181
    3. Individualized Molecular Medicine: Linking Functional Proteomics to Select Therapeutics Targeting the PI3K Pathway for Specific Patients
      Mandi M. Murph, Debra L. Smith, Bryan Hennessy, Yiling Lu, Corwin Joy, Kevin R. Coombes et al.
      Pages 183-195
    4. Defective Apoptosis Underlies Chemoresistance in Ovarian Cancer
      Karen M. Hajra, Lijun Tan, J. Rebecca Liu
      Pages 197-208
    5. Nanoparticle Delivery of Suicide DNA for Epithelial Ovarian Cancer Therapy
      Janet A. Sawicki, Daniel G. Anderson, Robert Langer
      Pages 209-219
    6. Biological Therapy with Oncolytic Herpesvirus
      Fabian Benencia, George Coukos
      Pages 221-233
    7. Cancer Immunotherapy: Perspectives and Prospects
      Sonia A. Perez, Michael Papamichail
      Pages 235-253

About these proceedings


Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field.

The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.


B7 family members BRCA Carcinom Epigenetic markers Ovarian Cancer Ovulatory factor Pathogenesis Regulatory T cells Vascular leukocytes classification genomic analysis microRNA p13K pathway

Editors and affiliations

  • George Coukos
    • 1
  • Andrew Berchuck
    • 2
  • Robert Ozols
    • 3
  1. 1.University of Pennsylvania Medical CenterPhiladelphiaUSA
  2. 2.Duke University Medical CenterDurhamUSA
  3. 3.Fox Chase Cancer CenterPhiladelphiaUSA

Bibliographic information

  • Copyright Information Springer Science + Business Media, LLC 2008
  • Publisher Name Springer, New York, NY
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-0-387-68966-1
  • Online ISBN 978-0-387-68969-2
  • Series Print ISSN 0065-2598